$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000162828018013896 Filed on November 07, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$3.300M	$2.550M	$1.597M
YoY Change	34.53%	59.67%	0.06%
Cost Of Revenue	$1.810M	$1.467M	$1.053M
YoY Change	7.74%	39.32%	-11.74%
Gross Profit	$1.490M	$1.083M	$544.0K
YoY Change	91.76%	99.08%	34.99%
Gross Profit Margin	45.15%	42.47%	34.06%
Selling, General & Admin	$5.290M	$5.891M	$5.640M
YoY Change	-23.11%	4.45%	11.62%
% of Gross Profit	355.03%	543.95%	1036.76%
Research & Development	$1.370M	$1.282M	$1.986M
YoY Change	-31.16%	-35.45%	-10.38%
% of Gross Profit	91.95%	118.37%	365.07%
Depreciation & Amortization	$350.0K	$280.0K	$420.0K
YoY Change	-18.6%	-33.33%	-10.64%
% of Gross Profit	23.49%	25.85%	77.21%
Operating Expenses	$6.630M	$7.177M	$7.610M
YoY Change	-24.05%	-5.69%	4.69%
Operating Profit	-$5.140M	-$6.094M	-$7.066M
YoY Change	-35.37%	-13.76%	2.91%
Interest Expense	-$130.0K	$145.0K	$165.0K
YoY Change	-66.67%	-12.12%	1962.5%
% of Operating Profit
Other Income/Expense, Net	$1.140M	-$889.0K	$731.0K
YoY Change	-275.38%	-221.61%	-145.35%
Pretax Income	-$4.130M	-$6.980M	-$6.340M
YoY Change	-54.01%	10.09%	-25.24%
Income Tax
% Of Pretax Income
Net Earnings	-$4.130M	-$6.983M	-$6.335M
YoY Change	-54.0%	10.23%	-25.28%
Net Earnings / Revenue	-125.15%	-273.84%	-396.68%
Basic Earnings Per Share		-$0.11	-$0.18
Diluted Earnings Per Share	-$988.0K	-$0.11	-$0.18
COMMON SHARES
Basic Shares Outstanding	62.64M shares	61.38M shares	34.72M shares
Diluted Shares Outstanding		61.38M shares	34.72M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.660M	$13.00M	$33.44M
YoY Change	-72.46%	-61.12%	161.25%
Cash & Equivalents	$7.655M	$13.00M	$33.44M
Short-Term Investments
Other Short-Term Assets	$280.0K	$510.0K	$2.190M
YoY Change	-79.1%	-76.71%	253.23%
Inventory	$3.371M	$3.361M	$2.380M
Prepaid Expenses
Receivables	$3.660M	$2.988M	$2.170M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.97M	$19.85M	$40.17M
YoY Change	-57.16%	-50.58%	128.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.365M	$2.170M	$2.300M
YoY Change	5.16%	-5.65%	-10.16%
Goodwill	$189.0K	$189.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$134.0K	$121.0K	$120.0K
YoY Change	9.84%	0.83%	33.33%
Total Long-Term Assets	$2.688M	$2.570M	$3.240M
YoY Change	-11.9%	-20.68%	-20.0%
TOTAL ASSETS
Total Short-Term Assets	$14.97M	$19.85M	$40.17M
Total Long-Term Assets	$2.688M	$2.570M	$3.240M
Total Assets	$17.66M	$22.42M	$43.41M
YoY Change	-53.52%	-48.35%	100.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.156M	$3.438M	$990.0K
YoY Change	30.41%	247.27%	-27.21%
Accrued Expenses	$3.489M	$3.469M	$2.750M
YoY Change	-0.4%	26.15%	19.05%
Deferred Revenue	$1.102M	$945.0K
YoY Change	-0.09%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.333M	$2.333M	$1.556M
YoY Change	9.07%	49.94%	2122.86%
Total Short-Term Liabilities	$10.08M	$10.19M	$6.590M
YoY Change	9.98%	54.55%	19.6%
LONG-TERM LIABILITIES
Long-Term Debt	$2.648M	$3.199M	$5.368M
YoY Change	-45.18%	-40.41%
Other Long-Term Liabilities	$119.0K	$27.00K	$1.780M
YoY Change	-13.77%	-98.48%	-77.44%
Total Long-Term Liabilities	$2.767M	$3.226M	$5.368M
YoY Change	-44.3%	-39.9%	-31.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.08M	$10.19M	$6.590M
Total Long-Term Liabilities	$2.767M	$3.226M	$5.368M
Total Liabilities	$14.93M	$16.84M	$13.74M
YoY Change	-10.06%	22.53%	2.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$171.1M	-$167.0M
YoY Change	18.72%
Common Stock	$63.00K	$63.00K
YoY Change	5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.728M	$5.587M	$29.67M
YoY Change
Total Liabilities & Shareholders Equity	$17.66M	$22.42M	$43.41M
YoY Change	-53.52%	-48.35%	100.78%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$4.130M	-$6.983M	-$6.335M
YoY Change	-54.0%	10.23%	-25.28%
Depreciation, Depletion And Amortization	$350.0K	$280.0K	$420.0K
YoY Change	-18.6%	-33.33%	-10.64%
Cash From Operating Activities	-$5.160M	-$4.210M	-$8.720M
YoY Change	-8.67%	-51.72%	35.4%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$20.00K	-$100.0K
YoY Change	-27.27%	-80.0%	-23.08%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.00K	-$20.00K	-$100.0K
YoY Change	-27.27%	-80.0%	-23.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-110.0K	3.370M	31.54M
YoY Change	-200.0%	-89.32%	114.41%
NET CHANGE
Cash From Operating Activities	-5.160M	-4.210M	-8.720M
Cash From Investing Activities	-80.00K	-20.00K	-100.0K
Cash From Financing Activities	-110.0K	3.370M	31.54M
Net Change In Cash	-5.350M	-860.0K	22.72M
YoY Change	-5.31%	-103.79%	179.12%
FREE CASH FLOW
Cash From Operating Activities	-$5.160M	-$4.210M	-$8.720M
Capital Expenditures	-$80.00K	-$20.00K	-$100.0K
Free Cash Flow	-$5.080M	-$4.190M	-$8.620M
YoY Change	-8.3%	-51.39%	36.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	ekso	Common Stock Contribution CommonStockContribution	0	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62642256	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EKSO BIONICS HOLDINGS, INC.
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Trading Symbol TradingSymbol	EKSO
CY2017Q4	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	136000	USD
CY2018Q3	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	214000	USD
CY2017Q4	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	121000	USD
	ekso	Supply Earn Out SupplyEarnOut	0	USD
	ekso	Stock Issued And Repurchase Of Warrants StockIssuedAndRepurchaseOfWarrants	0	USD
	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	417000	USD
	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	757000	USD
	ekso	Unrestricted Cash UnrestrictedCash	6615000	USD
	ekso	Common Stock Contribution CommonStockContribution	156000	USD
CY2018Q3	ekso	Contingent Success Fee Liability ContingentSuccessFeeLiability	33000	USD
	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	1828000	USD
	ekso	Cumulative Retrospective Adjustment To Retained Earnings CumulativeRetrospectiveAdjustmentToRetainedEarnings	171000	USD
	ekso	Cumulative Retrospective Adjustment To Retained Earnings CumulativeRetrospectiveAdjustmentToRetainedEarnings	0	USD
CY2018Q3	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	6380000	USD
CY2018Q3	ekso	Accrued Maintenance Current AccruedMaintenanceCurrent	78000	USD
CY2018Q3	ekso	Other Income Expense OtherIncomeExpense	-63000	USD
	ekso	Other Income Expense OtherIncomeExpense	-338000	USD
	ekso	Warrant Issuance WarrantIssuance	3301000	USD
CY2017Q3	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	16000	USD
	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	191000	USD
CY2018Q3	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	-4000	USD
	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	11000	USD
	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	42463000	USD
	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	0	shares
	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0	shares
	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	3961000	USD
	ekso	Product Maintenance Warranty Addition ProductMaintenanceWarrantyAddition	312000	USD
	ekso	Product Maintenance Warranty Expense ProductMaintenanceWarrantyExpense	287000	USD
CY2017Q4	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	353000	USD
CY2018Q3	ekso	Product Maintenance Warranty Liabilities Current Noncurrent ProductMaintenanceWarrantyLiabilitiesCurrentNoncurrent	378000	USD
CY2017Q4	ekso	Deferred Device Revenue DeferredDeviceRevenue	31000	USD
CY2018Q3	ekso	Deferred Device Revenue DeferredDeviceRevenue	34000	USD
CY2017Q4	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	1763000	USD
CY2018Q3	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2358000	USD
	ekso	Sales Earnout SalesEarnout	47000	USD
	ekso	Sales Earnout SalesEarnout	28000	USD
CY2018Q2	ekso	Selling And Marketing Expense Relating To Operating Lease Obligations SellingAndMarketingExpenseRelatingToOperatingLeaseObligations	175000	USD
CY2017	ekso	Defined Contribution Plan Maximum Annual Contributions Percentagethereafter DefinedContributionPlanMaximumAnnualContributionsPercentagethereafter	0.5
	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	72000	USD
	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	0	USD
	ekso	Warrant Issuance WarrantIssuance	0	USD
	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	508000	USD
	ekso	Stock Issued And Repurchase Of Warrants StockIssuedAndRepurchaseOfWarrants	2245000	USD
	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	13000	USD
CY2017Q3	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	-1067000	USD
	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	-1067000	USD
CY2017Q3	ekso	Other Income Expense OtherIncomeExpense	149000	USD
	ekso	Other Income Expense OtherIncomeExpense	220000	USD
CY2018Q3	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	0	USD
	ekso	Gain Loss On Repurchase Of Warrants GainLossOnRepurchaseOfWarrants	0	USD
CY2017Q3	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1814000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	4851000	USD
CY2018Q3	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-681000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-162000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
	ekso	Supply Earn Out SupplyEarnOut	189000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2420000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3438000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2760000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2988000	USD
	us-gaap	Accretion Expense AccretionExpense	72000	USD
	us-gaap	Accretion Expense AccretionExpense	64000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3503000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3469000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-340000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-183000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165825000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172721000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	650000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1755000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	938000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2232000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	212000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	59000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	63000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	55000	USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59943000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62617000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59943000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62617000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	60000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	63000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6457000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20500000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6939000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22703000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1919000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7007000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7007000	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9577000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9577000	shares
CY2017Q4	us-gaap	Assets Assets	37988000	USD
CY2018Q3	us-gaap	Assets Assets	22423000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	34937000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	19853000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	81000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	80000	USD
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	34000	USD
CY2018Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16846000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33439000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27813000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12995000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16593000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14818000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3396000	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3396000	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2480000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1103000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	945000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	816000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1535000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1267000	USD
CY2018Q3	us-gaap	Contractual Obligation ContractualObligation	2033000	USD
CY2018Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1053000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3608000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1467000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5217000	USD
CY2017Q4	us-gaap	Customer Advances And Deposits CustomerAdvancesAndDeposits	52000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1520000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	90000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1610000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2414000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2275000	USD
CY2018Q3	us-gaap	Customer Advances And Deposits CustomerAdvancesAndDeposits	56000	USD
CY2018Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5689000	USD
CY2018Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1011
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0992
CY2018Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-157000	USD
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	73000	USD
CY2018Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	32000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1103000	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	945000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	816000	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1535000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
	us-gaap	Depreciation Depreciation	1314000	USD
	us-gaap	Depreciation Depreciation	1174000	USD
CY2017Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1648000	USD
CY2018Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	1810000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	69000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-133000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	90000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	425000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-291000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-126000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7430000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2785000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9350000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	189000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	544000	USD
	us-gaap	Gross Profit GrossProfit	1292000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	1083000	USD
	us-gaap	Gross Profit GrossProfit	2819000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-750000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1058000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	488000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	109000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-577000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	477000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-86000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	297000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	557000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1239000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1463000	USD
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1299000	USD
CY2017Q4	us-gaap	Inventory Gross InventoryGross	3200000	USD
CY2018Q3	us-gaap	Inventory Gross InventoryGross	3697000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22423000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9165000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10185000	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	5532000	USD
CY2018Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2333000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	3025000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	3361000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1737000	USD
CY2018Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2144000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	175000	USD
CY2018Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	336000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	254000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	161000	USD
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2017Q4	us-gaap	Liabilities Liabilities	16597000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	16836000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37988000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1254000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1618000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-831000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	165000	USD
	us-gaap	Interest Expense InterestExpense	482000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	145000	USD
	us-gaap	Interest Expense InterestExpense	469000	USD
	us-gaap	Interest Paid Net InterestPaidNet	309000	USD
	us-gaap	Interest Paid Net InterestPaidNet	350000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	440000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2333000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2333000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	583000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3199000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4830000	USD
CY2018Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	3199000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42459000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2377000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-353000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25582000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17011000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6335000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20144000	USD
CY2018Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	130000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	589000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	157000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	79000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6983000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22860000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6335000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20144000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6983000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22860000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2139000	USD
CY2018Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	157000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7610000	USD
	us-gaap	Operating Expenses OperatingExpenses	24958000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	7177000	USD
	us-gaap	Operating Expenses OperatingExpenses	24710000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7066000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23666000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6094000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21891000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	138000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	347000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	121000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-356000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	44000	USD
CY2017Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	0	USD
CY2018Q3	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	488000	USD
CY2017Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	491000	USD
CY2018Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	90000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	731000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3522000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-889000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-969000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	353000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8036000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.82
CY2017Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	665000	USD
CY2018Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144154000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167014000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1597000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4900000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2550000	USD
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1339000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	509000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2017Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	232000	USD
CY2018Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	300000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2249000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2170000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-119000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	46000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1585000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1986000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7491000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1282000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4479000	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	311000	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	744000	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1369000	USD
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3M
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2018Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3226000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9563000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3106000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10892000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1755000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2232000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.04
CY2016Q4	us-gaap	Share Price SharePrice	8.00
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	230000	USD
	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	221000	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	21391000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	5587000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34720000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27425000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61381000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60721000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had no customers with an accounts receivable balance totaling </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total accounts receivable compared with one customer as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had no customers with sales of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total revenue, compared with one customer in the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">16%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had no customers with sales comprising </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company's total customer sales.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, the valuation of employee stock options and warrants, and contingencies. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-013896-index-headers.html	Edgar Link	pending
0001628280-18-013896-index.html	Edgar Link	pending
0001628280-18-013896.txt	Edgar Link	pending
0001628280-18-013896-xbrl.zip	Edgar Link	pending
ekso-093018x10q.htm	Edgar Link	pending
ekso-093018xex103.htm	Edgar Link	pending
ekso-093018xex311.htm	Edgar Link	pending
ekso-093018xex312.htm	Edgar Link	pending
ekso-093018xex321.htm	Edgar Link	pending
ekso-093018xex322.htm	Edgar Link	pending
ekso-20180930.xml	Edgar Link	completed
ekso-20180930.xsd	Edgar Link	pending
ekso-20180930_cal.xml	Edgar Link	unprocessable
ekso-20180930_def.xml	Edgar Link	unprocessable
ekso-20180930_lab.xml	Edgar Link	unprocessable
ekso-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2018 Q4 Form 10-Q Financial Statement

#000162828018013896 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2018 Q4 Form 10-Q Financial Statement

#000162828018013896 Filed on November 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso